Jean Holloway Sells 1,668 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 1,668 shares of the stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $59,530.92. Following the transaction, the senior vice president directly owned 152,203 shares in the company, valued at approximately $5,432,125.07. This represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Stock Performance

Artivion stock opened at $38.14 on Friday. The stock has a fifty day moving average price of $42.09 and a 200 day moving average price of $43.05. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The firm has a market capitalization of $1.83 billion, a P/E ratio of 190.71 and a beta of 1.59. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s quarterly revenue was up 19.2% on a year-over-year basis. Equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its stake in shares of Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares in the last quarter. XTX Topco Ltd acquired a new position in Artivion during the 4th quarter worth approximately $746,000. Susquehanna Portfolio Strategies LLC boosted its holdings in Artivion by 21.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock worth $1,849,000 after acquiring an additional 7,186 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in Artivion in the fourth quarter valued at approximately $248,000. Finally, Millennium Management LLC raised its stake in shares of Artivion by 1.0% during the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock valued at $4,188,000 after purchasing an additional 893 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Analysts Set New Price Targets

A number of analysts have recently commented on AORT shares. Canaccord Genuity Group dropped their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Citizens Jmp boosted their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Finally, Oppenheimer reissued an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.